Fujifilm Diosynth Biotechnologies Expands Cell-Culture Capacity - - BioPharm International

ADVERTISEMENT

Fujifilm Diosynth Biotechnologies Expands Cell-Culture Capacity


Fujifilm Diosynth Biotechnologies will expand its cell-culture manufacturing capabilities by adding two, 2000-L single-use bioreactors. One each of these is being installed at the company's sites in Research Triangle Park (RTP), NC, USA and Billingham, UK.

The new reactors will complement the range of vessels at both sites, adding further flexibility for customer requirements. Each site currently operates 1000-L single-use bioreactors with 250-L to 1000-L operating volumes, with an additional 200-L single-use bioreactor in the UK, and a 2000-L stainless steel train in RTP, which has been in place for a number of years manufacturing a range of products.

"The addition of these two new bioreactors will meet the demand we are seeing for a 2000-L platform, and offer a cost-effective, low-risk route to market through 'scaling-out' from early phase to commercial manufacture," said Steve Bagshaw, CEO Fujifilm Diosynth Biotechnologies, in a press release. The new bioreactors are expected to be operational by November 2014 in the US and in the UK in January 2015.

Source: Fujifilm Diosynth Biotechnologies

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
FDA Releases Guidance Electronic Submission of Lot Distribution Reports
September 5, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Author Guidelines

Click here